Resources

OK, I admit defeat. The UK government has published 3.5 key strategies that affect our sector in a week and I’m expecting at least two more in the coming days – a full analysis of so much text by today is beyond me but…

Laverock Therapeutics closes additional seed funding round, bringing total raised to more than £20 million.

In this latest white paper, Dave Cooper, Project Pursuit Manager at Emerson, explores how forward-thinking biotech companies can meet the growing demand for personalised treatments by reimagining their manufacturing strategies.

OutSee, announced it has secured £1.8 million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures.

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026

The average size of artificial intelligence (AI) deals was significantly higher than deals across the wider UK equity market in 2024, underlining the continued focus on the sector, reveals the British Business Bank’s annual Small Business Equity Tracker, published today.

Gastronomica, Pioneer Group’s cutting-edge food tech hub, was crowned winner of the Innovative Workplace Design award at the Property Week and Construction News Life Sciences & Research Clusters Awards.

The Data (Use and Access) Act became law last week – but what does it mean for the life science sector? Fredericka Argent, Paul Maynard, and Tom Griffiths from Covington and Burling’s technology regulatory team explain all in this blog.

Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.

Revolutionary network of national scanners accelerates diagnosis and drug development to deliver patient benefit

Discovery Park opened its doors for the East Kent Science Jamboree, hosting a record-breaking 1,500 children from 51 Kent schools for a two-day science spectacular.

Aravax announced the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company’s Oxford, UK site.

Tailor Bio announced the publication of a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.

Present Made, Eddington, is leading the way with Cambridge’s first purpose-built, large-scale corporate letting scheme – a pioneering development that brings 21st-century executive living to one of the UK’s most dynamic science and technology hubs.

The new site reflects Stratagem’s growth as a forward-thinking IP partner, offering clarity, simplicity and relevance across every stage of the client journey.

Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies.

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months.